Active immunotherapy in colorectal cancer

Area of Science:

• Oncology
• Immunotherapy

Background:

• Colon and rectal cancers (Dukes' B2-C3) present significant therapeutic challenges.
• Current treatment paradigms often involve surgery, radiation, and chemotherapy.

Purpose of the Study:

• To evaluate the efficacy of active specific immunotherapy (ASI) combined with standard treatment for colon and rectal cancer.
• To assess the impact of ASI on recurrence and survival rates in patients with advanced-stage colorectal cancer.

Main Methods:

• A prospectively randomized controlled trial involving 74 patients with Dukes' B2-C3 colon or rectal cancer.
• Patients were randomized to resection alone (control) or resection plus ASI with an autologous tumor cell-BCG vaccine.
• Rectal cancer patients received adjuvant pelvic irradiation; all patients were followed for a median of 56 months.

Main Results:

• The ASI group demonstrated a statistically significant improvement in time-to-recurrence (P = .037) and time-to-death (P = .031) compared to the control group.
• The observed benefits were primarily driven by the subgroup of patients with colon cancer.
• While encouraging, the small patient numbers preclude definitive conclusions about ASI's proven therapeutic benefit.

Conclusions:

• Active specific immunotherapy (ASI) with an autologous tumor cell-BCG vaccine shows a trend towards improved outcomes in advanced colorectal cancer.
• Further investigation in larger, multi-institutional trials is warranted to confirm the therapeutic value of ASI.
• The ongoing national trial aims to provide more robust evidence on the efficacy of ASI in colorectal cancer treatment.